openPR Logo
Press release

Deadline on August 20th upcoming in Lawsuit for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA)

08-14-2019 08:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on August 20, 2019 in the lawsuit for certain investors in Teva Pharmaceutical Industries Limited.

A Deadline is coming up on August 20, 2019 in the lawsuit for certain investors in Teva Pharmaceutical Industries Limited.

The Shareholders Foundation announced that a deadline is coming up on August 20, 2019 in the lawsuit filed for certain investors of Teva Pharmaceutical Industries Limited (NYSE: TEVA over alleged securities laws violations by Teva Pharmaceutical Industries Limited.

Investors who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and there are strict and short deadlines running. Deadline: August 20, 2019. NYSE: TEVA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that the defendants made false and/or misleading statements denying that Teva “engaged in any conduct that would give rise to liability” in various antitrust proceedings and investigations that enveloped the company. In truth, and as Defendants failed to disclose to investors, (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Those who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on August 20th upcoming in Lawsuit for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA) here

News-ID: 1822392 • Views: 915

More Releases from Shareholders Foundation

Care.com, Inc. (NYSE: CRCM) Long-Term Investors Notice: Investigation over possi …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors Care.com, Inc.. Investors who are current long term investors in Care.com, Inc. (NYSE: CRCM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NYSE: CRCM stocks follows a lawsuit filed against Care.com, Inc. over alleged securities laws violations. The investigation
Investigation announced for Long-Term Investors in shares of Exxon Mobil Corpora …
An investigation was announced for long-term investors in shares of Exxon Mobil Corporation (NYSE: XOM) concerning potential breaches of fiduciary duties by certain directors of Exxon Mobil. Investors who are current long term investors in Exxon Mobil Corporation (NYSE: XOM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE:
Investgiation for Investors in shares of Mobile TeleSystems (NYSE: MBT) over pot …
Certain directors of Mobile TeleSystems (NYSE: MBT) are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in Mobile TeleSystems (NYSE: MBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NYSE: MBT stocks follows a lawsuit filed against Mobile TeleSystems over alleged securities laws violations. The
Investigation announced for Investors in shares of Grubhub Inc. (NYSE: GRUB)
An investigation was announced on behalf of investors of Grubhub Inc. (NYSE: GRUB) shares over potential securities laws violations by Grubhub Inc. Investors who purchased shares of Grubhub Inc. (NYSE: GRUB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Grubhub Inc. (NYSE: GRUB) concerning whether

All 5 Releases


More Releases for Teva

Global Generic Drugs Market 2018 - Valeant, Zydus Cadila, Hikma, Teva
Accord Market, recently published a detailed market research study focused on the “Generic Drugs Market” across the global, regional and country level. The report provides 360° analysis of “Generic Drugs Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Generic Drugs on the
Global Trazodone Hydrochloride (API) Market 2018 - Teva, Angelini, Mylan, Fermio …
Apex Market Reports, recently published a detailed market research study focused on the “Trazodone Hydrochloride (API) Market” across the global, regional and country level. The report provides 360° analysis of “Trazodone Hydrochloride (API) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Trazodone
Global Capecitabine Market 2018 - Roche, Teva, Mylan, Hikma, Cipla
Apex Market Reports, recently published a detailed market research study focused on the “Capecitabine Market” across the global, regional and country level. The report provides 360° analysis of “Capecitabine Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Capecitabine on the basis of
Global Perphenazines Market 2018 - Teva, Sandoz, Endo, Mylan
Apex Market Reports, recently published a detailed market research study focused on the “Perphenazines Market” across the global, regional and country level. The report provides 360° analysis of “Perphenazines Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Perphenazines on the basis of
Global Calcitriol Market 2017- Teva, Strides Arcolab, Cadila Pharmaceuticals
Global Calcitriol Market 2017, presents a professional and in-depth study on the current state of the Calcitriol market globally, providing basic overview of Calcitriol market including definitions, classifications, applications and industry chain structure. Historical data available in the report elaborates on the development of the Calcitriol market on a global and regional level. The report compares this data with the current Calcitriol state of the market and thus discuss upon
Desipramine Market Size 2017-2022 Pfizer, Teva, Emcure, Novartis, Mylan
Global Desipramine Market Research Report Recently published a detailed market study on the "Desipramine Market" across the global, regional and country level. The report on the global Desipramine market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The Desipramine market report further provides production, capacity, Desipramine market price per region, gross margin, production cost, for all major regions and countries